| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.0006 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.006 |